Compound half-life reference

Derived from the published model rates. Testosterone enanthate 200 mg/mL in sesame oil (West-Ward), as studied in the IM reference cohort.; Intramuscular. Ten adult men with hypogonadism already receiving IM testosterone enanthate; adult model reanalysis of the 2015 cohort..

Derived from the published model rates. Testosterone cypionate depot injection studied in the repeated-dose cohort analyzed by Bi et al.; Intramuscular. Population PK model derived from 31 healthy adult men; the display uses its typical fixed parameters rather than individual fitted parameters..

Tmax reported; half-life inferred and rounded from the 48–72 h decline in Fig 1 (~10 to~4.5 ng/mL), about 21 h. Use 24 h as an explicit approximate shape assumption.

33.9 day terminal from Behre 1999; 7 day Tmax from current Nebido label is total testosterone. Combining these yields only a relative illustrative shape.

• The faster rate is inferred to match the 168 h source-scoped peak time; absorption half-life 35.580899063328104 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• The 14-person 1999 formulation and current Nebido label describe different kinetic summaries; 33.9 day terminal and 90 day release half-life are not interchangeable.
• No source-matched baseline/suppression model was established here. Use relative output while retaining a stated castor-oil timing scenario.
• Stored 0.65 resembles an ester mass fraction, not a demonstrated systemically available fraction.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (120 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Retain 20 day/8.5 day timings only as assumptions, not measured MCT kinetics.
• Unknown formulation concentration, injection volume, site, population, and absolute exposure.
• Do not infer MCT bioavailability from nominal ester-to-testosterone mass fraction.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (4.6 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Total testosterone includes baseline and suppression; a per-dose additive amplitude was not established.
• The 18.4 h terminal shape and 4.9 h Tmax require product-specific interpretation; retained only as assumptions.
• The historical research paper uses testosterone-equivalent doses; JATENZO strength is testosterone-undecanoate mass. Do not swap these bases.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (15 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Standalone timing remains an illustrative assumption.
• Ester mass fraction is not an independently measuredF.
• Never sum total-blend testosterone endpoints as separate ester contributions.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (18.6 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Standalone timing remains an illustrative assumption.
• Ester mass fraction is not an independently measuredF.
• Never sum total-blend testosterone endpoints as separate ester contributions.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (8.25 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 33 h/6 h parameters are retained only as animal-informed shape assumptions; not measured human suspension PK.
• The supplied CSV itself says its multiplier was adjusted to match other esters.
• No validated human dose-to-concentration or particulate formulation mapping was established.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (33.6 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Standalone timing remains an illustrative assumption.
• Ester mass fraction is not an independently measuredF.
• Never sum total-blend testosterone endpoints as separate ester contributions.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (17.9 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 71.6 h is not confirmed as a single-dose topical terminal half-life by this label.
• Keep only a clearly assumed relative skin-depot shape until product-specific baseline-corrected dynamics are fitted.
• Absorbed 10% must not be applied again to an already observed serum endpoint; application site/strength are not interchangeable.

Male 5 mg cyclodextrin single-dose study timing; illustrative when applied to generic sublingual products.

• The faster rate is inferred to match the 0.3333333333333333 h source-scoped peak time; absorption half-life 0.08103482259146995 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Suggested relative shape uses male cyclodextrin 5 mg timing; it does not establish troche PK or a 25 mg routine dose.
• No baseline-corrected concentration endpoint was recovered.

Estro Gel label apparent terminal half-life; legacy 4-hour Tmax not verified as universal.

• Absorption half-life is assumed to be one quarter of the slower timescale (9 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not fit repeated total estradiol as per-dose exogenous amplitude.
• Gel mass in grams is not estradiol mass inmg.
• Application area/washing/product affect absorption; present timing as formulation-specific.

Approximate peak timing from Oriowo human IM study; stored 89.65 h terminal rate not established by this source. The retained 89.650000008 h slower timescale is an assumption.

• The faster rate is inferred to match the 96 h source-scoped peak time; absorption half-life 50.73857155001672 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Widely repeated 337–338 pg/mL at 5 mg is a total-estradiol endpoint; baseline treatment must be established before an exogenous model.
• Arachis-oil study is not proof that every carrier/SC formulation shares kinetics.
• Keep numerical dose serialization; no automatic ester-mass/F multiplier.

Approximate Oriowo human IM peak; legacy 84 h half-life remains an assumption, not proven by the label. The retained 84 h slower timescale is an assumption.

• The faster rate is inferred to match the 48 h source-scoped peak time; absorption half-life 16.385732568003874 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not adopt the commonly repeated 667 pg/mL total peak as an exogenous per-dose peak without baseline handling.
• Oral estradiol valerate and IM valerate are different routes.

Legacy 22.78 h/1.5 h from a repeated-dose capsule study cannot establish universal per-dose kinetics. The retained 22.78 h slower timescale is an assumption.

• Absorption half-life is assumed to be one quarter of the slower timescale (5.695 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Food, soft vs hard capsule, first-pass metabolites and assay cross-reactivity materially affect measured exposure.
• Baseline progesterone and serum/plasma assay must be specified; no invented 10% F.

Crinone 90 mg label terminal absorption-limited timing only; intrinsic elimination 5–20 min. Do not call 34.8 h elimination of circulating progesterone.

• The faster rate is inferred to match the 6.8 h source-scoped peak time; absorption half-life 1.4108234300580222 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• One-compartment using 34.8 h terminal tail overpredicts AUC 2.44-fold and daily peak 40.8 vs observed 15.97.
• 19.8% relative bioavailability already embodied in Cmax; not an extra scale.
• Gel/capsule/insert and local uterine action are not interchangeable.

Jonklaas 2015 observed timing;22 h depends on chosen late timepoints and endogenous physiology.

• The faster rate is inferred to match the 2.5 h source-scoped peak time; absorption half-life 0.4320654238413822 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Use 0.05 mg=50 mcg, not 50 mg.
• Endogenous suppression/redistribution mean subtracting one fixed baseline is not a complete repeated-dose exogenous model.
• Peak-normalized one-compartment AUC 0–24=4046,2.18×observed.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (66 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Retain ester-specific timing only as an explicit assumption.
• No route/formulation-matched human Cmax/reference-dose/volume calibration established in this search.
• Veterinary implants, oral parent metabolism and other esters do not identify an IM oil curve.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (9 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Retain ester-specific timing only as an explicit assumption.
• No route/formulation-matched human Cmax/reference-dose/volume calibration established in this search.
• Veterinary implants, oral parent metabolism and other esters do not identify an IM oil curve.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (48 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Retain ester-specific timing only as an explicit assumption.
• No route/formulation-matched human Cmax/reference-dose/volume calibration established in this search.
• Veterinary implants, oral parent metabolism and other esters do not identify an IM oil curve.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.93333325 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• The 224 min shape may be retained only as an explicit free-MENT analogy, with formulation mismatch visible in methods.
• Do not treat implant serum levels as a peak per injected milligram or apply the 0.87 ester mass fraction asF.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 48 h timing remains a convention/assumption, not primary PK verified here.
• Drostanolone ester-to-base fraction~0.84 is not empirical bioavailability.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (48 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 192 h timing is an explicit ester analogy.
• No parent-drug plasma endpoint or route/formulation-matched human dose reference established.

Midpoint of label 12–13 h terminal range; reportedTmax 1.6 h.

Table 4 empirical peak/time with reported absorption half-time.

Table 4 empirical peak/time with reported absorption half-time.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (84 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 336 h is retained only as an assumed human scenario; the equine paper reports 123 h terminal, not 14 days.
• Oil/ester preparation, species scaling and dose-to-human concentration are unresolved.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (54 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Unclear intended ester/product under the generic DHB entry; 216 h cannot be presented as a verified free-base half-life.
• A relative shape remains an explicitly assumed scenario until formulation-specific evidence is available.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.2498 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 5 h timing is an assumption.
• 0.88 matches approximate parent/acetate mass fraction and is not oral bioavailability.
• Urine recovery percentages and radiolabeled metabolites must not become parent plasma endpoints.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (63 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Keep 252 h half-life as an explicit legacy assumption only; label does not report that terminal value.
• A parent-concentration model must not be calibrated to total drug-related equivalents.
• Oil formulation is castor oil/benzylbenzoate; ester fraction is notF.

Primary crossover half-life 2 h; midpoint of reported 1–2 h peak times, no oral-specific point.

• The faster rate is inferred to match the 1.5 h source-scoped peak time; absorption half-life 0.6075545274580504 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Cannot select a point from pooled 40–150 ng/mL as the oral mean.
• StoredF 0.57 is not established by this relative-bioavailability experiment.
• MidpointTmax 1.5 h is an estimate within the reported 1–2 h range.

Tmax source 210 min÷60; 8 h is declared assumed terminal shape, not reverified primary parameter.

• The faster rate is inferred to match the 3.5 h source-scoped peak time; absorption half-life 1.0316907771179677 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Half-life 8 h retained as an explicit shape estimate; original abstract verifies peak/time but not terminal half or cohort count. Full article access was limited.
• Food state/formulation details and linear accumulation are not fully established.
• No extra 0.95 F multiplier; observed oral endpoint already contains absorption.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.3125 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 5.25 h timing and 0.95 F lack matched primary support in this pass; show timing as assumed and discardF amplitude.
• Equine plasma studies cannot establish human absolute concentration.

Human oral Tmax~3 h and IV parent terminal half 16 h; relative oral reconstruction, enterohepatic cycling omitted.

• The faster rate is inferred to match the 3 h source-scoped peak time; absorption half-life 0.6130751586112678 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No numeric parent Cmax in accessible abstract.
• 16 hIV terminal can inform relative terminal shape, not prove a simple oral profile.
• First-pass loss and parent-versus-metabolite separation preclude usingF 1 or total radioactivity as parent concentrations.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (2.25 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 9 h is an explicit assumed human timing, not a verified measured parameter here.
• F=1 is unsupported; no unit/reference-dose endpoint established.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (20.52 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 82.08 h/168 h values can only remain explicitly animal-informed/assumed relative shape; 7 dayTmax not verified by abstract.
• Human IM clinical effects do not calibrate a human drug-concentration curve.

Tmax oral-tablet mean verified; 9.5 h stays a conservative label-era assumption, not derived fromMCT 6.7 h.

• The faster rate is inferred to match the 1.6 h source-scoped peak time; absorption half-life 0.31469202358666837 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Exactmean dose/per-person dose-to-table mapping is absent; a cohort mean Cmax cannot be confidently assigned to 10 mg.
• A possible approximate reference is 8.45 mg (=0.1 mg/kg ×median 84.5 kg), but this is not a measuredmean dose and should require an explicitly accepted additional assumption.
• The 6.7 h mean belongs tobuccal MCT; tablets described as similar without a numericaltable half.
• Use relative output rather than silently choose a reference dose; fixed-dose FDA table remains a specific follow-up.

Legacy shape assumption only; no route-matched human timing confirmed in the checked sources. Do not call this a measured half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (2.50000025 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 10 h timing remains explicitly assumed; 0.5 F not verified.
• Do not borrow methylstenbolone-horse exposure or cell persistence as human methasterone half-life.

Study endpoint used in an estimated curve. Highly purified urinary hCG, Choriomon, subcutaneous injection; 24 healthy women aged 20–45 in a crossover pharmacokinetic analysis, with oral-contraceptive pituitary downregulation.

Omnitrope solution single-dose study EP2K-00-PhIAQ, N=24; apparent SC tail, not intrinsic IV elimination.

Derived from the published model rates. Subcutaneous semaglutide solution in the SUSTAIN phase III program; Subcutaneous. Published reference: 85 kg white, non-Hispanic female under 65 with type 2 diabetes and normal renal function.

Derived from the published model rates. Original oral semaglutide/SNAC formulation studied with 300 mg SNAC; first-generation Rybelsus context, not newer oral formulations; Oral tablet. Healthy 85 kg adult without type 2 diabetes; fixed published reference parameters, not an average patient.

Derived from the published model rates. Subcutaneous tirzepatide in the published pooled-study model, using its estimated relative-bioavailability scenario; Subcutaneous. Constructed adult female reference with type 2 diabetes: 90 kg and BMI 32.5 kg/m²; not a published average participant.

Coskun 2022 Table 1, 1 mg cohort: geometric mean terminal half-life134h; median Tmax48h.

Innovent Chinese label: Tmax7–28h, rounded mean terminal half-life about10days. Label apparent clearance .0368L/h and volume11.2L.

Current 88.78 h and 0.226 h peak unsupported for general human use. Recent overdose case half 18 h is context-specific and must not replace this with a supposedly universal half-life. The retained 88.77984000000001 h slower timescale is an assumption.

• Absorption half-life is assumed to be one quarter of the slower timescale (22.194960000000002 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Relative scenario only; do not attach a safe concentration threshold or clearance assurance.
• Rat prodrug, parent DNP, poisoning, and hemoperfusion are not interchangeable.

Adult 1 mg single-dose study, rather than pediatric repeated-dose source.

• The faster rate is inferred to match the 1.52 h source-scoped peak time; absorption half-life 0.19138648582453316 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• One-compartment Cmax /timing normalization predicts 594.14 ng·h/m L,40% above source 423; retain relative until a defensible multi-phase curve is established.
• No extra 80% F; no estradiol-suppression prediction.

Mauras 2003 male cohort; first sample 1 h already at peak; true Tmax could be earlier. Other populations/assays reportabout 24 h.

• The faster rate is inferred to match the 1 h source-scoped peak time; absorption half-life 0.17232608972767566 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• One-compartment AUC 223.47 is 6.14×source 36.4.
• Cohort includes adolescents; not a normative adult efficacy/safety reference.
• Drug concentration is not amount of estrogen suppression.

Yamamoto 1985 total unchanged parent; do not substitute newer R-enantiomer peaks.

• The faster rate is inferred to match the 2.5 h source-scoped peak time; absorption half-life 0.3786961309490016 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• A peak-normalized 35 h curve predicts~0.962 ng/mL after 40 mcg q 12 h vs reported 0.5–0.6 plateau; source constraints conflict.
• 0.04 mg=40 mcg; no extra 90% F.
• R-enantiomer and racemate values cannot be mixed.

Label terminal 120–168 h;144 h midpoint is a timing assumption.

• The faster rate is inferred to match the 5 h source-scoped peak time; absorption half-life 0.6364052012164843 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• One-compartment predicts steady mean 354.7 ng/mL (~2.91×122); biphasic parent kinetics and metabolites require more than aterminal exponential.
• Do not sum parent+N-desmethyl/endoxifen as equal drug action.
• Tablet dose is tamoxifen base equivalent, not mass of citrate salt.

Five-day timing is a legacy illustration; no single measured half-life for the mixture accepted. The retained 120 h slower timescale is an assumption.

• Absorption half-life is assumed to be one quarter of the slower timescale (30 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Two separate 15 ng/mL peaks at different times are not a 30 ng/mL mixture Cmax.
• Do not model enclomiphene alone as Clomid.

Fed-arm single-dose plasma/urine study, not an averaged generichalf-life.

Noh 2012 Femara reference arm;58.97 h mean terminal,1.5 h median peak.

• The faster rate is inferred to match the 1.5 h source-scoped peak time; absorption half-life 0.17875714080544616 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• One-compartment AUC 0–312=3233.92 vs 2079.69,1.555×.
• 99.9% bioavailability is not an extra factor on observed peaks.

Do not reuse hydroxylated-metabolite timing as parent; parent 1.37 h in Briciu 2014 baseline arm. The retained 16.9300000008 h slower timescale is an assumption.

• Absorption half-life is assumed to be one quarter of the slower timescale (4.2325000002 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Absolute calibration needs a consistent parent/isomer/phenotype model.
• Combining label 12 h with EM peak 1.66 predicts AUC 30.45 (~3.31×9.19), illustrating why mixed-study parameters are rejected.
• Hydroxylated metabolites and racemic parent are not interchangeable.

40 mgarmof Zhang 2006; not dose independent amplitude.

• The faster rate is inferred to match the 1.76 h source-scoped peak time; absorption half-life 0.26969499003130265 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• 40 to 80 mg doubling yields~5.55×peak in this cohort; linear dose scaling invalid.
• One-compartment 40 mg AUC 5851 vs 1611 (3.63×).
• Paper product described Micardis Plus; confirm coformulation before choosing a future fitted model.

Forgue 2006 pooled single-dose means; not an individualfit.

Coss 2016 study 1 parent drug;1 hmedian Tmax,22 hmean terminal.

• The faster rate is inferred to match the 1 h source-scoped peak time; absorption half-life 0.13530751987917727 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• One-compartment AUC 1834 is 2.44×source 752.3; long terminal phase has lower weight.
• 15 mg UI default is 5×selected 3 mg study, not verified individual dose response.
• No extra 100% F; relative fallback remains explicit until a multiphasic fit is established.

30 his midpoint ofpublished 24–36 h;3 happroximate first-dose peak fromoriginal Figure 1.

Approximately 4 h rat/dog preclinical time course; human timing explicitly unverified.

• Absorption half-life is assumed to be one quarter of the slower timescale (1 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not call 4 h a human measured half-life.
• No human absolute profile identified; retain relative with assumed timing.
• Animal allometry/scaling is not validated by a dose-conversion formula alone.

Limited oncology-study terminal estimate;6 hwasnot universal Tmax.

• Absorption half-life is assumed to be one quarter of the slower timescale (11.175 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No adequate single Bateman kernel from one patient terminal rate and multiple peaks.
• 10 mg extrapolation cannot be presented as measured healthy male PK.
• Doping microdose urine concentrations are not blood Cmax.

Stored 20 hnotverified; daily trial administration is not proof of 24 hhalf-life. The retained 20 h slower timescale is an assumption.

• Absorption half-life is assumed to be one quarter of the slower timescale (5 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No sourced human Cmax, reference amplitude or half-life found in this pass.
• Exposure units must be relative; no inferred blood scale via other SARMs.

Animal-derived oral terminal rate; not a human estimate validated by measurement.

• Absorption half-life is assumed to be one quarter of the slower timescale (2.975 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Using 11.9 h as an illustrative shape is allowed only with animal-derived/assumed human status.
• Do not scale rat Cmax to human by body mass conversion.

Caille 1993 single 500 mg tablet study; the 3.16 h plasma half-life belongs to that study, not the longer whole-blood half-life.

Uses parent-ezetimibe timing from the fasted 10 mg Ezetrol arm in Sun 2023: 19.38 h terminal half-life and 5 h median peak. Absorption rate is inferred, not directly measured.

• A first-order absorption half-life of 1.15596 h reproduces the selected 5 h peak with the study terminal rate.
• Enterohepatic recycling and the active glucuronide metabolite are not represented; a smooth single peak is a simplification.
• A single fixed 1 mg input peaks at 1 relative unit. This normalization is not a blood concentration or potency comparison.
• Linear dose scaling and repeated-dose addition illustrate a timing scenario; they are not validated estimates of total ezetimibe exposure or LDL response.
• An absolute one-compartment fit to the parent peak and timing would give AUC∞ 116.35 ng·h/mL versus the study 68.62 (+69.6%); its blood-level amplitude was therefore not adopted.

Derived from the published model rates. Empagliflozin oral tablets in pooled phase I–III type 2 diabetes studies; Oral. Fixed source reference: 50-year-old non-smoking, non-Asian man with type 2 diabetes, BMI 25 kg/m² and eGFR 100 mL/min/1.73 m².

The Propecia label gives a 4.5 h first-dose half-life and a 1.3 h last-dose peak time in healthy men. This simplified curve combines those timings as an explicit approximation; it is not a calibrated plasma model.

• Absorption half-life 0.315187 h is mathematically reconstructed to place the peak at 1.3 h; it was not directly measured.
• One 1 mg input has a peak of 1 relative unit, independent of the example dose. Linear scaling and repeated-dose addition are illustrative.
• The source peak 9.2 ng/mL and AUC 53 ng·h/mL are steady-state observations, not single-dose calibration.
• Saturable enzyme binding and low-dose nonlinearity are omitted; the curve cannot estimate DHT, treatment benefit or a personal stopping interval.

Fed conventional-capsule label study: single 80 mg in 74 healthy adults, parent isotretinoin plasma Tmax 5.3 h and terminal half-life 21 h. Absorption is reconstructed to match that peak time.

• Absorption half-life 1.214334 h is inferred from peak timing and terminal half-life, not a measured absorption rate.
• A single 1 mg input peaks at 1 relative unit; dose scaling and repeated-dose addition are mathematical illustrations.
• A peak-calibrated one-compartment fit would imply AUC 31108 ng·h/mL, versus the source 10004; absolute calibration is therefore withheld.
• Distribution, enterohepatic recycling and active metabolites are omitted. The curve does not measure acne benefit or determine a pregnancy-safe waiting interval.
• The formulation/food context is fixed; this is not an Absorica, Absorica LD or fasting-exposure model.

About 10 h elimination half-life from the 14-day oral-citrate trial; 2.5 h peak is an assumed midpoint of the 2–3 h range described in the 6-week trial and FDA review.

• Absorption half-life 0.570595 h is inferred from the selected 10 h tail and 2.5 h peak, not a published fitted rate.
• One 1 mg declared citrate input peaks at 1 relative unit. This normalization is not a citrate-to-base conversion.
• Dose-proportional scaling and repeated-dose addition are mathematical conveniences: observed drug exposure was not proportional across doses.
• The 6-week study drug curve cannot be reused as a single-dose absolute calibration; no Cmax is invented.
• Metabolites, CYP2D6 variability and hormonal feedback are not modeled. The drug curve does not estimate total testosterone, estradiol or sperm count.

US oral-tablet label: approximate 18 h plasma half-life and peak around 4 h after a fasting single 12 mg dose. These are simplified label timing values, not parasite-killing duration.

• Absorption is inferred to reproduce the stated peak time with the stated terminal rate; this is not a fitted source absorption parameter.
• A single 1 mg input has a peak of 1 relative unit by definition. Repeated-dose addition and linear scaling are mathematical assumptions; the example dose does not calibrate the curve.
• Different studies and fed states give substantially different timing/exposure. The model does not represent topical ivermectin or animal products.
• Matching label peaks and 18 h tail in one compartment overstates the matched FDA AUC 0–72; no absolute amplitude is assigned.

Walter-Sack 2009 Table 1: mean oral plasma half-life 18.3 h and Tmax 2.2 h after a single 500 mg aqueous solution in healthy adults. Transfer to other oral products or much lower doses is an assumption.

• Absorption is inferred to reproduce the stated peak time with the stated terminal rate; this is not a fitted source absorption parameter.
• A single 1 mg input has a peak of 1 relative unit by definition. Repeated-dose addition and linear scaling are mathematical assumptions; the example dose does not calibrate the curve.
• Aqueous solution timing is not a validated model of capsules, lozenges, extended-release tablets or IV treatment.
• Plasma, whole-blood and reduced/oxidized species results are not interchangeable. No conversion from dye color or drops to a blood concentration is made.
• Peak-normalizing 3905 ng/mL at 18.3 h predicts more than twice the observed AUC∞ 51171 ng·h/mL, so this entry intentionally has no absolute calibration.

One fasting INSPRA 50 mg reference arm: mean terminal half-life 4.56 h and median peak time 1.75 h.

Iitsuka 2014 Table 2 Study 2: single fasting 50 mg OCAS tablet in 12 healthy Japanese men, mean terminal half-life 31.9 h and peak time 3.5 h. These source timings are used as a simplified scenario.

• Absorption is inferred to reproduce the stated peak time with the stated terminal rate; this is not a fitted source absorption parameter.
• A single 1 mg input has a peak of 1 relative unit by definition. Repeated-dose addition and linear scaling are mathematical assumptions; the example dose does not calibrate the curve.
• The source curve has a faster distribution phase plus a slow terminal tail. A one-compartment curve cannot match its peak and overall exposure; no absolute amplitude is assigned.
• Actual oral exposure increases more than proportionally with dose. Linear relative scaling is only mathematical and must not be read as a blood-exposure ratio.
• The generic label terminal half-life is about 50 h in patients; that is a different source context and is not mixed into this study-specific timing.
• Food, sex, organ function and formulation affect exposure. This model does not represent immediate-release products or Myrbetriq granules.

Nielsen2026 Table5 normal hepatic function: half-life174h and Tmax45h.

NCT01667900, Part A Day1,1.5mg group: median Tmax48h; geometric mean half-life82.9h.

Symlin label Table5: Tmax21minutes=.35h; half-life48minutes=.8h.

Table4 first0.6mg dose Tmax23.7h; Results3.3 reports DG2 terminal half-life114h after repeated/escalated dosing.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Human route/formulation, systemic exposure, absorption and terminal kinetics were not established by the reviewed source. Cell permeability cannot supply oral bioavailability.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No matched human concentration/time endpoint was verified. Do not translate the primate experimental regimen into human calibration.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Product identity, free-base/salt basis and route must be specified before absolute calibration. The stored 12-hour timing is unsupported, not a source-backed elimination half-life.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not substitute IGF-1, intact IGF1Ec or tissue-expression time courses for isolated MGF blood kinetics.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (4.8 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• PEG size, conjugation and product identity are not specified. A PEG-containing delivery scaffold does not establish the circulation kinetics of a PEG-MGF conjugate.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Tracer radioactivity, parent analyte and human administered-product exposure are not interchangeable. Retained timing is an assumption.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Potency or duration of biological response is not an elimination half-life. No human product/route Cmax was verified.

30µg/kg cohort half-life5.8d from Teichman figure2;1.25h is midpoint assumption within reported1–1.5h peak window, not measured cohort mean.

• The faster rate is inferred to match the 1.25 h source-scoped peak time; absorption half-life 0.12313185117369821 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No study cohort mean weight recovered, so30µg/kg cannot become2mg or2.1mg without an explicit assumed reference weight.
• AUCt is to last sampling, not infinite; exact last measurable time differs by subject. Do not compare it as if AUCinf.
• DAC albumin-bound analyte assay and formulation are not interchangeable with free no-DAC GRF.
• With139.2h tail and1.25h assumed Tmax, a simple peak-normalized Bateman is unsuitable for reproducing the observed early/late profile.

Retained historical illustrative timing assumption only; no validated human SC half-life recovered for this specific form.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Identity/salt ambiguity persists; no-DAC is not the DAC molecule with a different schedule.
• No measured SC F,Tmax or concentration amplitude supports the current curve.
• Relative output must explicitly identify timing assumption.

Terminal half-life after15min IV infusion in healthy men; extrapolated to SC shape only. SC absorption remains assumed.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.5 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Vss is not automatically central volume in a two-compartment model.
• Do not use GH Cmax, EC50 or production rate as ipamorelin concentration.
• No substantiated human SC F or matched Cmax/ref-dose/Tmax recovered.

Soule1994 human IV disappearance half-time4.3±1.4min; using it for SC is a route extrapolation, not a measured SC terminal value.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.017916666666666668 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Historical Geref11–12min and6%SC figures were located only via secondary mirrors, not a primary label; not silently adopted.
• No matched SC concentration endpoint set recovered; do not borrow GH peaks.

Single EGRIFTA WR1.28mg SC dose in healthy subjects, same label study. Original2mg Egrifta26/38min values came after14days, not this single-dose WR formulation.

• The faster rate is inferred to match the 0.15 h source-scoped peak time; absorption half-life 0.06452204183467626 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Peak/Tmax/tail reconstruction gives AUC1.7866ng·h/mL versus1.172reported (+52.4%); do not call all endpoints reproduced.
• Either explicitly identify WR in model scope or keep generic formulation relative; never relabel saved2mg inputs as1.28mg.
• No additional F multiplier because peak includes availability.
• Source variability is large; means of endpoints need not define one typical individual curve.

Pihoker 1998: terminal beta half-life in prepubertal children with short stature after 1 µg/kg IV over 1 min. Applying this to catalog SC scenarios extrapolates route and population.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.1375 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No matched adult SC availability, Tmax or dose-calibrated peak recovered.
• The pediatric IV 7.4 ng/mL peak must not be attached to a generic 0.1 mg SC dose.
• A single compartment does not reproduce the source biexponential disposition.

Cabrales 2013: IV terminal half-life 2.5 ± 1.1 h; distribution half-life 7.6 ± 1.9 min. SC absorption was not measured.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.625 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• The study used larger weight-based IV exposures than typical catalog SC scenarios.
• No SC availability, Cmax or Tmax was established.
• This does not model GH concentration.

Historical illustrative assumption. The regulator review found no detailed clinical PK supporting a human plasma half-life. A 24 h GH/IGF effect duration is not a plasma half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.25 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not turn dog bioavailability into human availability.
• No retrieved human paired parent-drug dose, Cmax and Tmax support an absolute scale.
• Future product-specific LUM-201 work may provide calibration; no complete verified candidate was recovered here.

Illustrative midpoint of 12.5 days within the reported human 10–15 day range; not a published cohort mean.

• Absorption half-life is assumed to be one quarter of the slower timescale (75 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not infer a fixed absolute dose from mg/kg without an explicit reference weight.
• Native ActRIIB and the Fc fusion are different molecules.
• The proposed 300 h relative curve uses a range midpoint assumption; it predicts neither blood concentration nor muscle growth.

Dixon 1991: harmonic mean terminal phase of 1.4 h after IV infusion. SC absorption remains unknown.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.35 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No matched human SC calibration was recovered.
• The week-long radioactivity tail is not parent-acadesine elimination.
• Vss is not central volume; a monoexponential absolute model cannot be inferred from it.

The historical 9.6 h value falls inside the 4–13 h IV CKD label range, but is not a verified SC estimate. SC timing varies with dose and population; label Tmax is 5–24 h.

• Saved numerical amounts retain their original values. No conversion to milligrams or IU is established.
• Absorption half-life is assumed to be one quarter of the slower timescale (2.4 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not reinterpret legacy stored amounts as mass or IU.
• An IU conversion requires a separately verified serialization and migration contract.
• One SC curve cannot represent all CKD, cancer, dialysis and healthy populations.

Proposed 12 h is the midpoint of the Menopur 11–13 h FSH half-life range during multiple dosing. Single-dose Tmax 17.9 h belongs to a different phase and must not be combined blindly.

• Saved numerical amounts retain their original values. No conversion to milligrams or IU is established.
• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• FSH is not total menotropin, LH or hCG.
• No IU-to-mass conversion is adopted; saved amounts must not be reinterpreted.
• The proposed timing concerns the FSH component and multiple-dose study, not universal menotropin kinetics.
• A future FSH model is feasible after dose-unit mapping, baseline handling and matched model-shape verification.

Human gonadorelin hydrochloride SmPC: rapid plasma hydrolysis with about 4 min half-life; SC/IV diagnostic formulation.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.016666666666666666 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Acetate preparations are not demonstrated bioequivalent.
• The LH diagnostic response is not gonadorelin concentration.
• SC peak and availability remain uncalibrated.

KP54 IV half-life is about 27.6 min; KP10 is about 3.8–4.1 min. Neither establishes SC absorption for the generic product.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.115 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Clarify peptide identity beside the curve; do not silently treat all kisspeptin as KP54.
• Absolute calibration requires a known peptide length, analyte, route, assay and reference dose.
• This curve does not include endogenous peptide or predict gonadotropin responses.

Rat IM 100 microgram/kg saline BPC157: half-life 17.1 min, Tmax 3 min. The 2-person human IV pilot reports safety biomarkers, not peptide concentration calibration.

• The faster rate is inferred to match the 0.05 h source-scoped peak time; absorption half-life 0.009976653025332967 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Animal IM timing does not establish human SC absorption or elimination.
• Do not use total radiolabel half-life: the radiolabel includes metabolites and recycled amino acids.
• Rat/dog Cmax must not be scaled into a human blood estimate.

Ruff 2010:40 healthy volunteers, single 42–1260 mg IV then daily 14 days; dose-dependent half-life. The legacy 1.92 h is not a verified SC half-life.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.48 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Product sequence and route are unresolved for a generic TB-500 entry.
• Do not transplant the full-length IV peak or half-life to the 7-residue fragment.

The 2024 study examines human-serum/enzyme incubations and rat urine. Metabolite detection to 72 h is not the parent plasma half-life; legacy 0.96 h remains an assumption.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• No human parent-peptide systemic calibration established in reviewed sources.
• Ac-LKKTE wound-assay activity is a metabolite effect, not a blood exposure endpoint.

Rost 1999: nine Caucasian volunteers,900 microgram/m² SC, three-way formulation crossover, single and 5 day administration; Tmax 1–2 h, half-life<3 h. Use 2 h/1.5 h as explicitly inferred representative timing, not a reported fitted parameter pair.

• The faster rate is inferred to match the 1.5 h source-scoped peak time; absorption half-life 0.6075545274580504 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Zadaxin/Timosina/Talpha 1-HLR show different exposure.
• The 63 ng/mL at 1.6 mg value is present in a 2024 review but primary product/cohort linkage was not established in this pass.
• Apparent volumes/clearance already include F.

PKARA: healthy male crossover;4 mg SC n 5, Cmax 2.0±0.7 ng/mL, Tmax 6 min, AUC148 ng·min/mL, terminal~20 min. Later clinical paper summarizes~3 ng/mL; do not silently replace the original cohort mean.

• The faster rate is inferred to match the 0.1 h source-scoped peak time; absorption half-life 0.024645183502450502 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Source Cmax 2 ng/mL and AUC148 ng·min/mL imply an AUC/peak ratio 1.233 h; a 20 min/6 min one-compartment curve gives about 71 ng·min/mL, substantially below 148.
• Reported 2/4/6 mg SC peaks 1.6/2.0/7.4 ng/mL are not proportional across all tested amounts.
• Bioavailability and volume must not be invented.

Derived from the published model rates. Elamipretide hydrochloride solution, 40 mg active moiety in 0.5 mL in the source comparator.; Subcutaneous abdomen. Fixed tabulated SPICP-105 parameters from 41 healthy participants; no particular reference age or weight is asserted..

Legacy 12 h has no administered-human timing support in reviewed sources.

• Absorption half-life is assumed to be one quarter of the slower timescale (3 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not substitute the modified analog CB4211 or engineered R13A-MOTS-c for native MOTS-c.
• Endogenous biomarker concentrations cannot calibrate an entered exogenous dose.

Replace legacy 0.48 h with the reported horse IM terminal 0.68 h only as an explicitly animal-derived relative scenario. IV distribution 0.09 h and terminal 0.76 h are distinct. Do not apply the horse 47–100%IM bioavailability to people.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.17 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not borrow data for Lys 7-dermorphin fluorescent probes or dermorphin-ranatensin hybrids.
• A human intrathecal dose cannot calibrate a blood curve.

Legacy 0.96 h is an assumed display timescale, not measured mixture clearance.

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• The 215.2 mg/mL product concentration is preparation mass, not peptide Cmax.
• Do not assign a universal molecular weight to the complex or reinterpret saved milligram amounts as mL.

Legacy 4.08 h is an unverified scenario timescale; no concentration-time sampling in the inspected experiment.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• In-vitro assay concentration is not Cmax.
• Cartilage-patent claims do not establish a clinically measured half-life.

Legacy 4.08 h is an assumed timescale; the 0.05 ng/mL tissue-culture concentration is not a plasma peak.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not mistake cultured human donor cells for an administered-human study.
• No route-matched human PK established in reviewed sources.

Legacy 4.08 h is unverified; fluorescent-peptide uptake does not establish native peptide elimination.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not equate material-science KEDG adsorption or DNA binding with systemic exposure.
• No human exogenous-peptide calibration established in reviewed sources.

Legacy 4.08 h is an assumption; no timed parent-peptide plasma data in inspected originals.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not substitute activity duration or donor-cell aging endpoints for elimination.
• No route-specific F established.

Label apparent terminal half-life of 17.4 h is from uncorrected plasma after 20 mg/kg IV over 3 min; distribution half-life is 0.585 h. Endogenous baseline affects the terminal estimate. This is not a verified IM/SC tail.

• Absorption half-life is assumed to be one quarter of the slower timescale (4.35 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Do not borrow an oral steady-state peak for injection.
• Label clearance of 4 L/h and terminal 17.4 h include baseline and do not suffice for an exogenous-only model.
• The SC/IM 70% availability assumption is unsupported.

Retained only as an explicit mathematical timing assumption; not a verified human half-life. No concentration-unit amplitude is supported.

• Absorption half-life is assumed to be one quarter of the slower timescale (1.2 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Reviewed evidence does not establish the catalog’s 4.8-hour human half-life or bioavailability. No absolute human Cmax was verified.